Halozyme Thrp Stock Price, News & Analysis

Halozyme Therapeutics announced that Janssen Biotech received FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with Kyprolis (carfilzomib) and dexamethasone for adult patients with relapsed or refractory multiple myeloma. This marks the ninth indication for DARZALEX FASPRO. The approval is based on data from Janssen's PLEIADES Study, which achieved its primary endpoint of overall response rate. The product leverages Halozyme's ENHANZE technology, facilitating rapid treatment administration that may enhance patient experience.

Halozyme Therapeutics (NASDAQ: HALO) will participate in two upcoming investor conferences:

• 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22, 2021, featuring Elaine Sun in an on-demand chat.
• Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, with Dr. Helen Torley representing the company in a virtual chat.

Presentations can be accessed via the investors section of Halozyme.com, with recordings available for six months.

Halozyme Therapeutics reported Q3 2021 financial results, with revenues reaching $115.8 million, up 77% year-over-year, driven by a 145% increase in royalty revenue. The company expects full-year royalty revenue to more than double from 2020. Operating income rose to $75.6 million from $40.3 million in Q3 2020. Q3 net income surged to $216.6 million, influenced by a $142.5 million tax benefit. Halozyme also repurchased 4.4 million shares for $189.7 million through Q3. Revenue guidance for 2021 is now set between $430 million and $445 million.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host its Q3 2021 financial update on November 2 at 4:30 p.m. ET. CEO Dr. Helen Torley will lead the call, following the release of Q3 financial results for the period ending September 30, 2021. Interested investors can register for the call via Halozyme's website. The company's innovative ENHANZE® technology has aided over 500,000 patients through collaborations with leading pharmaceutical firms, enhancing treatment efficiency. A recording will be available post-call for those unable to attend.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that its CFO, Elaine Sun, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 1:20 p.m. ET. An audio-only link for the presentation will be available in the "Investors" section of the Halozyme website, with a recording accessible for six months post-event. Halozyme specializes in biopharmaceutical solutions to enhance patient experiences and outcomes, leveraging its ENHANZE® technology to reduce treatment times significantly. The company's partnerships with major pharmaceutical firms play a key role in its growth.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will have Dr. Helen Torley, CEO, present at the Wells Fargo 2021 Virtual Healthcare Conference on September 10, 2021, at 10:40 a.m. ET. An audio link to the presentation will be available on Halozyme's website, with a recording accessible for six months post-event. Halozyme specializes in biopharmaceuticals, aiming to enhance patient experiences through innovative solutions like the ENHANZE® technology, drastically reducing treatment times. The company collaborates with major pharmaceutical firms, providing its technology across global markets.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported strong financial results for Q2 2021, with revenue reaching $136.5 million, up from $55.2 million in Q2 2020, largely driven by $60 million in milestone revenues. The company announced a collaboration with ViiV Healthcare for its ENHANZE® technology, raising its 2021 revenue guidance to $425-$445 million. The net income for Q2 was $91.5 million, reflecting significant growth. Additionally, Halozyme repurchased 1 million shares for $48.8 million during the quarter, enhancing shareholder value.

Halozyme Therapeutics (NASDAQ: HALO) will be represented by Elaine Sun, CFO, in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:30 p.m. ET. The event will be accessible via an audio link on the company's website, with a recording available for six months. Halozyme focuses on biopharmaceuticals, utilizing its ENHANZE technology to improve treatment delivery, impacting over 500,000 patients through partnerships with major pharmaceuticals.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host its second quarter 2021 conference call on August 9 at 4:30 p.m. ET. The call will be led by CEO Dr. Helen Torley and will follow the release of financial results for the quarter ending June 30, 2021. Investors can register via a provided link, and the event will be webcast live on Halozyme's corporate site. Halozyme's technology aims to enhance patient experiences, with its solutions impacting over 500,000 patients globally through multiple commercialized products.